Pharmacologic therapies for the low cardiac output syndrome in children after cardiac surgery: evidence of their efficacy and trends in their use

Abstract

The low cardiac output syndrome describes the phenomenon of the reduction of cardiac output that can occur following cardiac surgery requiring cardiopulmonary bypass. If unrecognized or untreated, this condition can result in significant morbidity and mortality. Along with non-pharmacologic therapies, pharmacologic agents used to help manage the low cardiac output syndrome include catecholamine inotropes, inodilators, systemic vasodilators, pulmonary vasodilators, and other classes of medications. We summarize the rationale and key evidence supporting the use of these therapies in children. In addition, utilizing provider surveys and registry reviews, we describe the current trends in the use of these medications and the variation demonstrated between providers and centers. Given the heterogeneous etiology of low cardiac output syndrome, successful management requires that pharmacologic therapies be tailored to the physiologic derangements of each patient.

Keywords

Cardiac surgery / low cardiac output syndrome / pediatrics / cardiac critical care

References

[1] Wessel DL.Managing low cardiac output syndrome after congenital heart surgery.Crit Care Med2001;29:S220-30

[2] Gabay C.Acute-phase proteins and other systemic responses to inflammation.N Engl J Med1999;340:448-54

[3] Kozik DJ.Characterizing the inflammatory response to cardiopulmonary bypass in children.Ann Thorac Surg2006;81:S2347-54

[4] Aĝirbaşli M,Win K.Inflammatory and hemostatic response to cardiopulmonary bypass in pediatric population: feasibility of seriological testing of multiple biomarkers.Artif Organs2010;34:987-95

[5] Mcguinness J,Redmond J.Understanding the inflammatory response to cardiac surgery.Surgeon2008;6:162-71

[6] Ramaswamy V,Vandermeer B,Miller S.Systematic review of biomarkers of brain injury in term neonatal encephalopathy.Pediatr Neurol2009;40:215-26

[7] Epting CL,Wald EL.Pathophysiology of post-operative low cardiac output syndrome.Curr Vasc Pharmacol2016;14:14-23

[8] Bautista-Hernandez V,McCully JD.Cellular and molecular mechanisms of low cardiac output syndrome after pediatric cardiac surgery.Curr Vasc Pharmacol2016;14:5-13

[9] Parr GV,Kirklin JW.Cardiac performance and mortality early after intracardiac surgery in infants and young children.Circulation1975;51:867-74

[10] Wernovsky G,Jonas RA.Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest.Circulation1995;92:2226-35

[11] Hoffman TM,Atz AM.Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.Circulation2003;107:996-1002

[12] Du X,Song X.Risk factors for low cardiac output syndrome in children with congenital heart disease undergoing cardiac surgery: a retrospective cohort study.BMC Pediatr2020;20:87 PMCID:PMC7038550

[13] Ulate KP,Jeffries H,Di Gennaro JL.An elevated low cardiac output syndrome score is associated with morbidity in infants after congenital heart surgery.Pediatr Crit Care Med2017;18:26-33

[14] Roeleveld PP.The perspective of the intensivist on inotropes and postoperative care following pediatric heart surgery: an international survey and systematic review of the literature.World J Pediatr Congenit Heart Surg2018;9:10-21 PMCID:PMC5764149

[15] Loomba RS.Use of vasoactive agents in postoperative pediatric cardiac patients: insights from a national database.Congenit Heart Dis2019;14:1176-84

[16] Lechner E,Leitner-Peneder G.Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study.Pediatr Crit Care Med2012;13:542-8

[17] Momeni M,Matta A.Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.J Cardiothorac Vasc Anesth2011;25:419-24

[18] Burkhardt BE,Stiller B.Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.Cochrane Database Syst Rev2015;3:CD009515

[19] Appelbaum A,Kouchoukos NT.Afterload reduction and cardiac output in infants early after intracardiac surgery.Am J Cardiol1977;39:445-51

[20] Ranadive SM,Dillon G,Joyner MJ.Comparison of the vasodilatory effects of sodium nitroprusside vs. nitroglycerin.J Appl Physiol (1985)2017;123:402-6 PMCID:PMC5583612

[21] Stone ML,Mistry M,Gangemi J.Use of nicardipine after cardiac operations is safe in children regardless of age.Ann Thorac Surg2018;105:181-5

[22] Colucci WS,Horton DP.Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.N Engl J Med2000;343:246-53

[23] Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA2002;287:1531-40

[24] Sackner-Bernstein JD,Fox M.Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.JAMA2005;293:1900-5

[25] Tweddell JS,Mussatto KA.Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients.Circulation2002;106:I82-9

[26] Miller OI,Keech A,Beller E.Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study.Lancet2000;356:1464-9

[27] James C,Horton S,Molesworth C.Nitric oxide administration during paediatric cardiopulmonary bypass: a randomised controlled trial.Intensive Care Med2016;42:1744-52

[28] Kirbas A,Tanrikulu N,Isik O.Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery.Cardiol J2012;19:387-94

[29] Wong J,Evey L,Flores S.Postoperative inhaled nitric oxide does not decrease length of stay in pediatric cardiac surgery admissions.Pediatr Cardiol2019;40:1559-68

[30] Smith HA,Christian KG.Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline.J Thorac Cardiovasc Surg2006;132:58-65

[31] Bizzarro M,Barbosa FT.Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease.Cochrane Database Syst Rev2014;:CD005055

[32] Schlapbach LJ,Long DA.NITRIC Study Group, the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), the Paediatric Critical Care Research group (PCCRG) and the ANZICS Paediatric Study Group (PSG)Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): a randomised controlled trial.BMJ Open2019;9:e026664 PMCID:PMC6701583

[33] Graham EM,Butts RJ.Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial.J Thorac Cardiovasc Surg2011;142:1523-9 PMCID:PMC3161127

[34] Shore S,Pearl JM.Usefulness of corticosteroid therapy in decreasing epinephrine requirements in critically ill infants with congenital heart disease.Am J Cardiol2001;88:591-4

[35] Hall RI,Rocker G.The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations.Anesth Analg1997;85:766-82

[36] Li Y,Wu X,Yan F.Perioperative corticosteroid therapy in children undergoing cardiac surgery: a systematic review and meta-analysis.Front Pediatr2020;8:350 PMCID:PMC7396528

[37] Graham EM,Buckley JR.Corticosteroid therapy in neonates undergoing cardiopulmonary bypass: randomized controlled trial.J Am Coll Cardiol2019;74:659-68 PMCID:PMC6684326

[38] Flores S,Iliopoulos I.An international survey of corticosteroid use for the management of low cardiac output syndrome.Pediatr Crit Care Med2017;18:630-7 PMCID:PMC5503756

[39] Hill KD,Bichel DP.STRESS Network InvestigatorsRationale and design of the STeroids to REduce Systemic inflammation after infant heart Surgery (STRESS) trial.Am Heart J2020;220:192-202 PMCID:PMC7008076

[40] Bettendorf M,Tiefenbacher U,Heinrich UE.Transient secondary hypothyroidism in children after cardiac surgery.Pediatr Res1997;41:375-9

[41] Mackie AS,Newburger JW.A randomized, double-blind, placebo-controlled pilot trial of triiodothyronine in neonatal heart surgery.J Thorac Cardiovasc Surg2005;130:810-6

[42] Marwali EM,Darmaputri S.Oral Triiodothyronine supplementation decreases low cardiac output syndrome after pediatric cardiac surgery.Pediatr Cardiol2019;40:1238-46

[43] Portman MA,Olson AK.TRICC InvestigatorsTriiodothyronine supplementation in infants and children undergoing cardiopulmonary bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.Circulation2010;122:S224-33 PMCID:PMC3090076

[44] Marwali EM,Budiwardhana N.Oral triiodothyronine for infants and children undergoing cardiopulmonary bypass.Ann Thorac Surg2017;104:688-95

[45] Flores S,Checchia PA,Bronicki RA.Thyroid hormone (triiodothyronine) therapy in children after congenital heart surgery: a meta-analysis.Semin Thorac Cardiovasc Surg2020;32:87-95

[46] Alten JA,Toms R,Moellinger A.Early initiation of arginine vasopressin infusion in neonates after complex cardiac surgery.Pediatr Crit Care Med2012;13:300-4

[47] Bigelow AM,Thompson NE.Safety and efficacy of vasopressin after fontan completion: a randomized pilot study.Ann Thorac Surg2019;108:1865-74

[48] Rizza A,Belletti A.Vasoactive Drugs and hemodynamic monitoring in pediatric cardiac intensive care: an italian survey.World J Pediatr Congenit Heart Surg2016;7:25-31

[49] Yuerek M,Mascio CE.Postoperative management of heart failure in pediatric patients.Expert Rev Cardiovasc Ther2016;14:201-15

[50] Mascio CE,Jacobs JP.Perioperative mechanical circulatory support in children: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database.J Thorac Cardiovasc Surg2014;147:658-64: discussion 664-5 PMCID:PMC3926808

[51] Coskun KO,Coskun ST.Extracorporeal life support in pediatric patients with congenital heart diseases: outcome of a single centre.Minerva Pediatr2010;62:233-8